Table 1 Demographics, clinical characteristics and treatment of patients recovered from COVID-19 with positive results of SARS-CoV-2
From: Positive results for patients with COVID-19 discharged form hospital in Chongqing, China
Patients (n = 61) | |
|---|---|
Age, years | 54.79 (12.89) |
≤ 29 | 3 (4.9%) |
30–39 | 7 (11.5%) |
40–49 | 12 (19.7%) |
50–59 | 18 (29.5%) |
60–69 | 15 (24.6%) |
70–79 | 6 (9.8%) |
Sex | |
Female | 36 (59%) |
Male | 25 (41%) |
Chronic medical illness | 24 (39.3%) |
Chronic obstructive pulmonary disease | 8 (13.1%) |
Hypertension | 5 (8.2%) |
Diabetes | 5 (8.2%) |
Digestive system disease | 2 (3.3%) |
Cerebrovascular disease | 1 (1.6%) |
Chronic kidney disease | 1 (1.6%) |
Chronic hepatitis | 2 (3.3%) |
Symptoms after discharge from hospital | |
Fever | 15 (24.6%) |
Sore throat | 8 (13.1%) |
Cough | 11 (18%) |
Shortness of breath | 3 (4.9%) |
Sputum production | 9 (14.8%) |
Headache | 5 (8.2%) |
Fatigue | 3 (4.9%) |
Diarrhoea | 3 (4.9%) |
Asymptom | 38 (62.3%) |
Positive results | |
Nasal and pharyngeal swab | 36 (59%) |
Stool | 17 (27.9%) |
Sputum | 8 (13.1%) |
Disease severity status | |
Mild | 38 (62.3%) |
General | 20 (32.8%) |
Severe | 3 (4.9%) |
Critical | 0 |
Laboratory findings | |
Leucocyte count (× 109 per L; normal range 3.5–9.5) | 6.9 (4.5–8.5) |
> 9.5 | 8 (13.1%) |
< 3.5 | 11 (18%) |
Neutrophil count (× 109 per L; normal range 1.8–6.3) | 4.9 (3.4–5.9) |
> 6.3 | 14 (22.9%) |
Lymphocyte count (× 109 per L; normal range 1.1–3.2) | 1.5 (0.8–1.9) |
< 0·8 | 17 (27.9%) |
Platelets count (× 109 per L; normal range 100–300) | 155 (128–175) |
< 100 | 4 (6.6%) |
Procalcitonin, ng/mL (normal range < 0.05) | |
≥ 0.05, n (%) | 6 (9.8%) |
C-reactive protein (mg/L; normal range 0–5) | 3.2 (1.7–28.6) |
≥ 5.0 | 19 (31.1%) |
D-dimer (mg/L; normal range 0–500) | 164 (65–327) |
> 500 | 7 (11.5%) |
Albumin (g/L; normal range 40–55) | 33.7 (28.4–37.6) |
< 40 | 58 (95.1%) |
Alanine aminotransferase (U/L; normal range 9–50) | 27 (19–36) |
> 50 | 5 (8.2%) |
Aspartate aminotransferase (U/L; normal range15–40) | 24 (15–33) |
> 40 | 4 (6.6%) |
Blood urea nitrogen (mmol/L; normal range3.6–9.5) | 6.1 (4.7–7.3) |
> 9.5 | 5 (8.2%) |
Serum creatinine (μmol/L; normal range 57–111) | 80 (67–95) |
> 111 | 9 (14.8%) |
Lactate dehydrogenase (U/L; normal range 120–250) | 172 (150–262) |
> 250 | 14 (22.9%) |
Radiologic findings | |
Abnormalities on chest radiograph | 23 (37.7%) |
Ground-glass opacity | 3 (4.9%) |
Local patchy shadowing | 9 (14.8%) |
Bilateral patchy shadowing | 8 (13.1%) |
Interstitial abnormalities | 3 (4.9%) |
Normalities on chest radiograph | 38 (62.3%) |
Length of stay in hospital, days | 18.0 (14.0–22.5) |
Length of positive result for COVID-19 after hospital discharge, days | 10 (7–13) |
< 14 | 47 (77%) |
14–28 | 9 (14.8%) |
> 28 | 5 (8.2%) |
Treatment | |
Oxygen therapy | 21 (34.4%) |
Non-invasive mechanical ventilation | 2 (3.3%) |
Antiviral treatment | 23 (37.7%) |
Antibiotic treatment | 20 (32.8%) |
Glucocorticoids | 2 (3.3%) |
Convalescent plasma therapy | 3 (4.9%) |
Clinical outcomes at data cutoff | |
Hospitalization | 22 (36.1%) |
Hospital Discharge | 1 (1.6%) |
Centralized isolation for medical observation | 38 (62.3%) |